⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JNJ News
Johnson & Johnson
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026
prnewswire.com
JNJ
Las principales organizaciones sanitarias se reúnen en Washington para celebrar el liderazgo en materia de salud y presentar el Fondo de Acción de la Fundación Nacional para la Salud de los Hispanos
prnewswire.com
UNH
PFE
CNC
JNJ
Leading Health Organizations Unite in Washington to Celebrate Health Leadership and Launch the National Hispanic Health Foundation Action Fund
prnewswire.com
PFE
JNJ
CNC
Dupixent, Skyrizi, Tremfya, Keytruda, Darzalex, and Hemlibra Among Patient Support Leaders as New Spherix Global Insights Research Reveals What Sets Top Programs Apart
globenewswire.com
REGN
ABBV
JNJ
MRK
PFE
Coultreon Biopharma Appoints Nate Massari as Chief Business Officer
globenewswire.com
JNJ
AZN
CCRN
Dry Bulk, Gas, & Tanker Shipping Industry Leaders Presenting at Capital Link’s 18th Annual New York Maritime Forum – Wednesday, September 30, 2026, New York City
globenewswire.com
CTRM
NMM
TORO
SBLK
DSX
GNK
ZIM
INSW
NVGS
PAA
VAL
OSG
BW
DHT
HAFN
LPG
NAT
RIG
VLO
ARCC
BNTX
CRIS
CYTK
EXAS
FGEN
GILD
IMUX
INCY
MRNA
NTLA
REGN
RGNX
VRTX
ALNY
AMGN
AZN
BMY
CHKP
CTAS
CVX
DDOG
DELL
DIS
DLTR
DOCU
DOX
DV
EA
EBAY
ECL
EFX
EGY
EL
ENPH
EQIX
ERIC
ETSY
EVTC
EW
EXC
FSLR
FTNT
GE
GPN
GRMN
HAS
HLT
IBM
IDXX
ILMN
INTC
INTU
ISRG
JAZZ
JBL
JD
JNJ
JPM
KDP
KHC
KLAC
KMB
KMI
KO
LBRDK
LRCX
LULU
LYFT
MAR
MCHP
MDLZ
MELI
MGM
MKTX
MLM
MNST
MRVL
MSFT
MU
NDAQ
NFLX
NOC
NTAP
NVDA
NXPI
ORCL
ORLY
OTIS
PANW
PAYX
PCAR
PDD
PEP
PFE
PGR
PHG
PHI
PPC
PRGO
PSA
PSN
PTC
PYPL
QCOM
QRVO
RCL
RDNT
REG
REI
ROKU
ROST
RS
SBUX
SCL
SE
SEDG
SIRI
SLB
SMCI
SNOW
SNPS
SO
SPG
SRE
SRPT
STX
SWKS
SYK
SYY
T
TCOM
TEAM
TEVA
TGT
TJX
TM
TMO
TMUS
TSLA
TXN
TXRH
UAL
ULTA
UMC
UNH
UNP
UPS
URI
USB
V
VRSK
VSAT
VTR
VZ
WAB
WDC
WEC
WFC
WHR
WMB
WMT
WST
XEL
XOM
XRAY
XYL
YETI
YMM
ZBRA
ZION
ZTS
Orphan Drugs Market - Global Forecast 2026-2032 Now Available, Analyzes Biologics, Gene Therapy, Small Molecules, and Tissue Therapy
globenewswire.com
ABBV
ALNY
AMGN
BMRA
BMY
GILD
INCY
JNJ
NVS
PFE
REGN
VRTX
Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer
globenewswire.com
JNJ
Small Molecule Drug Discovery Market Outlook 2026-2030: Investment Trends, Strategic Profiles and Revenue Share Outlook
globenewswire.com
JNJ
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
prnewswire.com
JNJ